Target Validation Information
Target ID T20973
Target Name Cell division protein kinase 5
Target Type
Discontinued
Drug Potency against Target SCH 727965 Drug Info IC50 < 5 nM [537564]
AT7519 Drug Info IC50 = 13 nM [537564]
Thieno analogue of kenpaullone Drug Info IC50 = 4000 nM [526916]
R-roscovitine Drug Info IC50 = 270 nM [537564]
1-phenyl-3-(2-(pyridin-4-yl)thiazol-4-yl)urea Drug Info IC50 = 2990 nM [528986]
MANZAMINE A Drug Info IC50 = 1500 nM [528991]
3-(2-phenylthiazol-4-yl)quinolin-2(1H)-one Drug Info IC50 = 1400 nM [528992]
KENPAULLONE Drug Info IC50 = 850 nM [526916]
AZAKENPAULLONE Drug Info IC50 = 4200 nM [526916]
References
Ref 537564Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
Ref 537564Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
Ref 526916Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6.1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta.
Ref 537564Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
Ref 528986Bioorg Med Chem. 2007 Oct 15;15(20):6574-95. Epub 2007 Jul 25.Structure-activity relationships of 3,4-dihydro-1H-quinazolin-2-one derivatives as potential CDK5 inhibitors.
Ref 528991J Nat Prod. 2007 Sep;70(9):1397-405. Epub 2007 Aug 21.Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for Alzheimer's disease.
Ref 528992Bioorg Med Chem Lett. 2007 Oct 1;17(19):5384-9. Epub 2007 Aug 6.Design and synthesis of quinolin-2(1H)-one derivatives as potent CDK5 inhibitors.
Ref 526916Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6.1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta.
Ref 526916Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6.1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.